These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
597 related articles for article (PubMed ID: 28868758)
21. PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis. Liu T; Greenberg M; Wentland C; Sepe B; Bowe S; Diercks G; Huynh T; Mino-Kenudson M; Schlegel R; Kodack D; Benes C; Engelman J; Hartnick C Int J Pediatr Otorhinolaryngol; 2017 Apr; 95():133-138. PubMed ID: 28576522 [TBL] [Abstract][Full Text] [Related]
22. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996 [TBL] [Abstract][Full Text] [Related]
23. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. Gibbons Johnson RM; Dong H Front Immunol; 2017; 8():961. PubMed ID: 28848559 [TBL] [Abstract][Full Text] [Related]
24. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470 [TBL] [Abstract][Full Text] [Related]
26. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264 [TBL] [Abstract][Full Text] [Related]
27. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497 [TBL] [Abstract][Full Text] [Related]
28. Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. Morimoto Y; Kishida T; Kotani SI; Takayama K; Mazda O Biochem Biophys Res Commun; 2018 Dec; 507(1-4):330-336. PubMed ID: 30446226 [TBL] [Abstract][Full Text] [Related]
29. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. Liu H; Shen J; Lu K Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435 [TBL] [Abstract][Full Text] [Related]
30. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer. Tanaka T; Kutomi G; Kajiwara T; Kukita K; Kochin V; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T; Okamoto Y; Hirata K; Sato N; Tamura Y Oncotarget; 2017 Apr; 8(15):24706-24718. PubMed ID: 28160557 [TBL] [Abstract][Full Text] [Related]
32. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Sampedro-Núñez M; Serrano-Somavilla A; Adrados M; Cameselle-Teijeiro JM; Blanco-Carrera C; Cabezas-Agricola JM; Martínez-Hernández R; Martín-Pérez E; Muñoz de Nova JL; Díaz JÁ; García-Centeno R; Caneiro-Gómez J; Abdulkader I; González-Amaro R; Marazuela M Sci Rep; 2018 Dec; 8(1):17812. PubMed ID: 30546030 [TBL] [Abstract][Full Text] [Related]
33. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656 [TBL] [Abstract][Full Text] [Related]
34. PD-L1 Expression and CD8 Wang Y; Zhu C; Song W; Li J; Zhao G; Cao H J Immunol Res; 2018; 2018():4180517. PubMed ID: 30003113 [TBL] [Abstract][Full Text] [Related]
35. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma. Hollander P; Amini RM; Ginman B; Molin D; Enblad G; Glimelius I PLoS One; 2018; 13(9):e0204870. PubMed ID: 30261066 [TBL] [Abstract][Full Text] [Related]
37. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Wang Y; Wu L; Tian C; Zhang Y Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997 [TBL] [Abstract][Full Text] [Related]
38. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404 [TBL] [Abstract][Full Text] [Related]
39. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299 [TBL] [Abstract][Full Text] [Related]
40. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Prima V; Kaliberova LN; Kaliberov S; Curiel DT; Kusmartsev S Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1117-1122. PubMed ID: 28096371 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]